Table 2.

Longitudinal pulmonary details

Patient No.	Months since MMF start	MMF dose (mg daily)	Pred- nisone dose (mg daily)	DLCO	FVC	FEV1/ FVC (%)	TLC	SpO2 (on room air)	Wt (lbs)	Medication changes after PFT results	Dyspnea
1	−6	0	0	46	77	81	70	84% (walk) 93% (rest)	217	Began prednisone 60 mg daily	DOE for 2 months
1	−3	0	40	80	125	79	119	94% (walk) 97% (rest)	217	Began prednisone taper	DOE improved
1	−1	0	30	70	99	82	99	NA	217	1 month later: increased prednisone to 60 mg daily (taper after 2 months), MMF added	DOE increased
1	13	3000	10.5	79	106	78	99	96% (rest)	200	Continued prednisone taper	No DOE
1	24	3000	3	83	104	79	97	96% (rest)	217	Finished prednisone taper over next 4 months	No DOE
1	37	2000	0	88	121	78	89	95% (rest)	230	Continued MMF taper (began taper 4 months ago)	No DOE
2	0	0	0	37	76	83	77	NA	200	Began prednisone 60 mg daily and MMF	Noted DOE in retrospect
2	7	3000	25	76	82	77	83	97% (rest)	216	Continued prednisone taper (began taper 2 months ago)	No DOE
2	14	2000	4	82	87	78	85	98% (rest)	214	Continued prednisone taper	No DOE
3	−1	0	7.5	44	65	87	73	NA	305	1 month later: added MMF, increased prednisone to 40 mg daily, stopped methotrexate (12.5 mg weekly)	Noted DOE in retrospect
3	5	3000	40	77	69	86	71	100% (rest)	363	Started prednisone taper	No change in DOE
4	−1	0	15	66	73	69	56	NA	210	1 month later: MMF added, prednisone taper started	Mild DOE
4	6	3000	10	69	64	78	77	99% (rest)	207	Continued prednisone taper	DOE improved
4	12	3000	4	82	83	83	86	100% (rest)	211	Continued prednisone taper	No DOE

All PFT values (DLCO, FVC, FEV1, TLC) except FEV1/FVC are percent of predicted value. DLCO=diffusing capacity for carbon monoxide, DOE=dyspnea on exertion, FEV1=forced expiratory volume in one second, FVC=forced vital capacity, MMF=mycophenolate mofetil, PFT=pulmonary function test, SpO2=saturation of peripheral oxygen, TLC=total lung capacity